InsideTrading SEC Form 4 insider trades
← All clusters
BBTX

Bambusa Therapeutics, Inc.

Healthcare Biological Products, (No Diagnostic Substances) Market cap: not available Ticker page → Watch BBTX (just your e-mail) Price alert (just your e-mail)

Limited buying: $58.6M bought (counted up to $5.0M); 3 distinct insiders. Holding it back: largest buyer: Kolchinsky Peter (Director), 80% of the dollars.

AI summary Insiders and major shareholders buy shares in Bambusa Therapeutics IPO

39
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. <60 · limited buying
+1.7%
Since the cluster formed, vs benchmark (+0.1% raw)

Score, not a recommendation.

Total bought$58.6M6 Form 4 purchases
Distinct insiders3open-market buyers
Insiders' average price$15.83+1.6% to the latest close
Cluster window2026-10-30 → 2026-11-02active

partial dataAn input is missing, usually the market cap or the price history. A missing input counts as neutral in the score and is never estimated. Market cap is missing; missing inputs count as neutral in the score.

Price and insider purchases

Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.

Loading price history…

How the score adds up

How each input is counted →
Points each input adds to the score, and how much of the points it could give it has
Input Strength Points
$58.6M bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. 100% +57
3 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. 48% +7
No CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. 0% +0
Stock 0% below its 1-year highHow far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. 0% +0
3 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. 95% -1
Routine or plan purchases: 0% of the dollarsThe share of the dollars in routine or plan purchases (a Rule 10b5-1 plan, dividend reinvestment, a regular cadence). All of it routine would take off 5.6 points. 100% +0
Largest buyer: Kolchinsky Peter (Director), 80% of the dollarsThe share of the dollars bought by the largest buyer. Buying spread evenly keeps the points; one buyer paying for everything takes off 12.7. 31% -10
Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast.53
AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results.-14
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation.39

Why are they buying?

AI · ipo_offering · catalyst none · documented

Insiders and major shareholders purchased shares in connection with the company's initial public offering on the Nasdaq Global Select Market.

Bambusa Therapeutics began trading its common stock on October 30, 2026, following the automatic conversion of preferred stock into common stock upon the completion of its initial public offering.

Transactions

6 Form 4 trades · 3 insiders Download CSV Up to 5,000 rows
Purchases in this cluster, grouped by insider, largest first
Date InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. Role Shares Price Value Filing
2026-10-30 → 2026-11-02 Kolchinsky Peter history of Kolchinsky Peter's purchases Director 2,953,820 $15.79 avg $46.6M
2026-10-30 Kolchinsky Peter 263,911 $14.92 $3.9M SEC filing for Kolchinsky Peter (opens in a new tab)
2026-10-30 Kolchinsky Peter 189,909 $14.23 $2.7M SEC filing for Kolchinsky Peter (opens in a new tab)
2026-11-02 Kolchinsky Peter 164,891 $16.00 $2.6M SEC filing for Kolchinsky Peter (opens in a new tab)
2026-11-02 Kolchinsky Peter 2,335,109 $16.00 $37.4M SEC filing for Kolchinsky Peter (opens in a new tab)
2026-11-02 Jeggle Helmut Wolfgang history of Jeggle Helmut Wolfgang's purchases Director 375,000 $16.00 $6.0M SEC filing for Jeggle Helmut Wolfgang (opens in a new tab)
2026-11-02 Salvia Investment GmbH history of Salvia Investment GmbH's purchases 10% owner 375,000 $16.00 $6.0M SEC filing for Salvia Investment GmbH (opens in a new tab)
Total $58.6M

What happened next

A buying runPurchases at one company with no pause longer than the cluster rule allows. A long pause ends the run, so one company can have several. ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmarkThe index a stock's return is compared with: a small-cap index for small companies, a large-cap index otherwise. (IWM for small companies, SPY otherwise), from the first open after the buying run became a cluster. Past results, not a forecast.

After this buying run became a cluster, vs benchmark: 21 days –63 days –126 days –